Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms
Standard
Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. / Smolkova, Bozena; Kataki, Agapi; Earl, Julie; Ruz-Caracuel, Ignacio; Cihova, Marina; Urbanova, Maria; Buocikova, Verona; Tamargo, Sandra; Rovite, Vita; Niedra, Helvijs; Schrader, Joerg; Kohl, Yvonne.
in: CRIT REV ONCOL HEMAT, Jahrgang 180, 103865, 12.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms
AU - Smolkova, Bozena
AU - Kataki, Agapi
AU - Earl, Julie
AU - Ruz-Caracuel, Ignacio
AU - Cihova, Marina
AU - Urbanova, Maria
AU - Buocikova, Verona
AU - Tamargo, Sandra
AU - Rovite, Vita
AU - Niedra, Helvijs
AU - Schrader, Joerg
AU - Kohl, Yvonne
N1 - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2022/12
Y1 - 2022/12
N2 - Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.
AB - Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.
KW - Humans
KW - Neuroendocrine Tumors/diagnosis
KW - Pancreatic Neoplasms/diagnosis
KW - Neoplasm Recurrence, Local
KW - Liquid Biopsy
KW - Prognosis
U2 - 10.1016/j.critrevonc.2022.103865
DO - 10.1016/j.critrevonc.2022.103865
M3 - SCORING: Review article
C2 - 36334880
VL - 180
JO - CRIT REV ONCOL HEMAT
JF - CRIT REV ONCOL HEMAT
SN - 1040-8428
M1 - 103865
ER -